10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
Tg Therapeutics Inc. (TGTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Soleus Capital Guy Levy | 2,846,703 | $112,245,499 | +7% | 8.08% |
| 2. | Hood River Capital Management David Swank | 1,556,488 | $61,372,322 | +7% | 1.05% |
| 3. | Driehaus Capital Richard Driehaus | 774,656 | $30,544,686 | 0.29% | |
| 4. | Citadel Investment Group Ken Griffin | 645,877 | $25,466,931 | +26% | 0% |
| 5. | 555,600 | $21,907,308 | +72% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.13 | 100,000 | Officer, Director | 12,073,021 | 2023-08-11 | Filing | |
| $10.64 | 9,000 | Director | 201,848 | 2023-01-06 | Filing | |
| $7.04 | 50,000 | 12,878,185 | 2019-06-26 | Filing | ||
| $6.53 | 114,855 | Large Shareholder | 5,114,855 | 2015-02-17 | Filing | |
| $3.43 | 10,000 | Large Shareholder, Officer, Director | 7,839,471 | 2013-12-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.53 | 10,021 | Officer | 660,611 | 2025-01-06 | Filing | |
| $30.29 | 11,337 | Officer | 670,632 | 2025-01-03 | Filing | |
| $30.44 | 5,000 | Director | 100,195 | 2024-11-11 | Filing | |
| $30.20 | 25,000 | Director | 212,479 | 2024-11-11 | Filing | |
| $24.48 | 20,000 | Director | 224,098 | 2024-11-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,494,972 | $847,546,746 | 0.02% | |
| 2. | 15,604,512 | $615,285,908 | 0.01% | |
| 3. | 7,433,899 | $293,118,638 | 0.01% | |
| 4. | 3,282,567 | $129,460,067 | 0.01% | |
| 5. | 2,644,457 | $104,270,934 | 0.09% |
News See All
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2025 Earnings Call Transcript
Operator: Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast. At this time, all participants are in a listen-only mode.
10 Best Short Squeeze Stocks to Buy According to Analysts
Stock market trading has an ever-changing environment. Short squeeze is among the few phenomena capable of capturing and holding the attention of such markets.
10 Best Performing Growth Stocks in 2025
Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the TG Therapeutics' Fourth Quarter and Full Year Conference Call and Webcast. At this time, all participants are in a listen-only mode.
12 Hot Stocks to Buy According to Analysts
While the stock market in the United States remained closed on January 20 for Martin Luther King, Jr. Day, the day was happening with Donald Trump's inauguration on the same date.
Why TGTX Stock Is Rallying Today
The company estimated today that its 2024 revenue from the MS treatment had come in at $310 million.
Should You Invest in TG Therapeutics (TGTX)?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Stocks That Will Make You Rich In 2025
Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock market in 2025.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the TG Therapeutics' Third Quarter Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
